Items Tagged ‘brentuximab vedotin’

October 6th, 2015

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma

By

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the journal Blood. Hodgkin’s lymphoma is a type of cancer of the immune system. Standard therapy for Hodgkin’s often includes […]

View full entry

Tags: adcetris, brentuximab vedotin, CD30., Hodgkin's Lymphoma, MMAE, News, Progressive Relapsed Hodgkin's Lymphoma


May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

By

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]

View full entry

Tags: adcetris, Autologous Stem Cell Transplant, brentuximab vedotin, HL, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma, refractory, relapsed